title: [Molecular target therapy for non-Hodgkin lymphoma].
abstract: Non-Hodgkin lymphomas(NHL) encompass various types of lymphoid neoplasms with different biological behavior. Comprehensive genomic analysis identifies novel mutation and signaling pathways in various tumors, which leads to rational approaches in cancer therapy. Molecular target therapy is a new approach focusing on specific protein or signaling pathways. Molecules of signaling pathways of B-cell receptor, PI3K/Akt/mTOR and NF-kappaB are rational target, and many new drugs targeting the pathways are developing in various subtypes of lymphoma. Monoclonal and novel conjugated antibodies for cell surface proteins, epigenetic modulators and immunomodulatory agents also show promising clinical activities. This review will focus on the new molecular target drugs and their activity in NHL.
authors.forename: Harumi
authors.initials: H
authors.lastname: Kato
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Kinoshita
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D001897:Boronic Acids / Q000627:therapeutic use; D000069286:Bortezomib; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D058990:Molecular Targeted Therapy; D011719:Pyrazines / Q000627:therapeutic use; D000069283:Rituximab; D015398:Signal Transduction / Q000187:drug effects
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D001897:Boronic Acids; D011719:Pyrazines; D000069283:Rituximab; D000069286:Bortezomib; C119496:tositumomab I-131; C527517:ofatumumab; C543332:obinutuzumab